Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats

References

• Andrade C. (2012). Drug interactions in the treatment of depression in patients with ischemic heart disease. J Clin Psychiatry 73:e1475–7
   PubMedGoogle Scholar
• Andrade C, Sandarsh S, Chethan KB, et al. (2010). Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 71:1565–75
   PubMed Web of Science ®Google Scholar
• Ariyo AA, Haan M, Tangen CM, et al. (2000). Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 102:1773–9
   PubMed Web of Science ®Google Scholar
• Aronow HD, Steinhubl SR, Brennan DM, et al. (2009). Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention; insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Hear J 157:369–74
   PubMed Web of Science ®Google Scholar
• Bahrami G, Mohammadi B, Sisakhtnezhad S. (2008). High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: application to a bioequivalence study. J Chromatogr B 864:168–72
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, et al. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–36
   PubMed Web of Science ®Google Scholar
• Brosen K, Skielbo E, Rasmussen BB, et al. (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211–14
   PubMed Web of Science ®Google Scholar
• Caplain H, Donat F, Gaud C, et al. (1999). Pharmacokinetics of clopidogrel. Semin Thomb Hemost 25:25–8
   PubMed Web of Science ®Google Scholar
• Chen X, Jin J, Chen Y, et al. (2015). Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. Biopharm Drug Dispos 36:64–8
   PubMed Web of Science ®Google Scholar
• Clarke TA, Waskell LA. (2003). The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31:53–9
   PubMed Web of Science ®Google Scholar
• Delavenne X, Magnin M, Basset T, et al. (2013). Investigation of drug–drug interactions between clopidogrel and fluoxetine. Fundam Clin Pharmacol 27:683–9
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. (2010). Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126–42
   PubMed Web of Science ®Google Scholar
• Glassman AH, Shapiro PA. (1998). Depression and the course of coronary artery disease. Am J Psychiatry 155:4–11
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, et al. (1998). Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 59:19–27
   PubMed Web of Science ®Google Scholar
• Hagihara K, Kazui M, Ikenaga H, et al. (2009). Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica 39:218–26
   PubMed Web of Science ®Google Scholar
• Hantsoo L, Czarkowski KA, Child J, et al. (2014). Selective serotonin reuptake inhibitors and endothelial function in women. J Womens Health (Larchmt) 23:613–18
   PubMed Web of Science ®Google Scholar
• Harris J, Heil JS. (2013). Managing depression in patients with advanced heart failure awaiting transplantation. Am J Health Syst Pharm 70:867–73
   PubMed Web of Science ®Google Scholar
• Herbert JM, Frehel D, Vallee E, et al. (1993). Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180–98
   Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D, et al. (2001). Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–7
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92–9
   PubMed Web of Science ®Google Scholar
• Ksycinska H, Rudzki P, Bukowska-Kiliszek MJ. (2006). Determination of clopidogrel metabolite (SR26334) in human plasma by LC–MS. J Pharm Biomed Anal 41:533–9
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB, et al. (2003). Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 107:32–7
   PubMed Web of Science ®Google Scholar
• Lespérance F, Frasure-Smith N, Juneau M, et al. (2000). Depression and 1-year prognosis in unstable angina. Arch Intern Med 160:1354–60
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. (2000). The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21:2033–41
   PubMed Web of Science ®Google Scholar
• Mullangi R, Srinivas NR. (2009). Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug–drug interaction studies. Biomed Chromatogr 23:26–41
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, DeVane CL, Pollock BG. (1996). Newer antidepressant and the cytochrome P450 system. Am J Psychiatry 153:311–20
   PubMed Web of Science ®Google Scholar
• Nirogi RV, Kandikere VN, Shukla M, et al. (2006). Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:1695–700
   PubMed Web of Science ®Google Scholar
• O’Donoghue M, Wiviott SD. (2006). Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 114:e600–6
   PubMed Web of Science ®Google Scholar
• Pal D, Mitra AK. (2006). MDR- and CYP3A4-mediated drug–drug interactions. J Neuroimmune Pharmacol 1:323–39
   PubMed Web of Science ®Google Scholar
• Plosker GL, Lyseng-Williamson KA. (2007). Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 67:613–46
   PubMed Web of Science ®Google Scholar
• Rand ML, Leung R, Packham MA. (2003). Platelet function assays. Transfus Apher Sci 28:307–17
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Nagayama M, Masaoka T, et al. (1997). Effects of fenthion, isoxathion, dichlorvos and propaphos on the serum cholinesterase isoenzyme patterns of dogs. Vet Hum Toxicol 39:1–5
   PubMedGoogle Scholar
• Sandson NB, Armstrong SC, Cozza KL. (2005). An overview of psychotropic drug–drug interactions. Psychosomatics 46:464–94
   PubMed Web of Science ®Google Scholar
• Saruwatari J, Yasui-Furukori N, Niioka T, et al. (2012). Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol 32:195–9
   PubMed Web of Science ®Google Scholar
• Savi P, Herbert JM. (2005). Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31:174–83
   PubMed Web of Science ®Google Scholar
• Savi P, Laplace MC, Maffrand JP, et al. (1994). Binding of [3H]-2-methylthio ADP to rat platelets – effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772–7
   PubMed Web of Science ®Google Scholar
• Schmider J, Greenblatt DJ, von Moltke LL, et al. (1997). Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylaton. Br J Clin Pharmacol 44:495–8
   PubMed Web of Science ®Google Scholar
• Song X, Siahaan TJ. (2002). Synthesis and stability study of a modified phenylpropionic acid linker-based esterase-sensitive prodrug. Bioorg Med Chem Lett 12:3439–42
   PubMed Web of Science ®Google Scholar
• Souri E, Jalalizadeh H, Kebriaee-Zadeh A, et al. (2006). Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 20:1309–14
   PubMed Web of Science ®Google Scholar
• Tagashira H, Bhuiyan MS, Shioda N, et al. (2014). Fluvoxamine rescues mitochondrial Ca2+ transport and ATP production through σ(1)-receptor in hypertrophic cardiomyocytes. Life Sci 95:89–100
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolysed by distinct carboxylesterases, and clopidogrel is transesterifiated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76
   PubMed Web of Science ®Google Scholar
• Taubert D, Kastrati A, Harlfinger S, et al. (2004). Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92:311–16
   PubMed Web of Science ®Google Scholar
• Thornton LA. (2001). Depression in post-acute myocardial infarction patients. J Am Acad Nurse Pract 13:364–7
   PubMedGoogle Scholar
• Weiss J, Dormann SM, Martin-Facklam M, et al. (2003). Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197–204
   PubMed Web of Science ®Google Scholar
• Xu ZH, Xie HG, Zhou HH. (1996). In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 42:518–21
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Takahata T, Nakagami T, et al. (2004). Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487–94
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–22
   PubMed Web of Science ®Google Scholar